[
    [
        {
            "time": "",
            "original_text": "独立董事身兼“8”职？贝达药业收深交所关注函 关注函",
            "features": {
                "keywords": [
                    "独立董事",
                    "身兼多职",
                    "贝达药业",
                    "深交所",
                    "关注函"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "独立董事身兼“8”职？贝达药业收深交所关注函 关注函",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "新提名董事同时任职8家公司遭问询 贝达药业称不违规 问询",
            "features": {
                "keywords": [
                    "新提名董事",
                    "8家公司",
                    "贝达药业",
                    "问询"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "新提名董事同时任职8家公司遭问询 贝达药业称不违规 问询",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝达药业控股股东减持1673万股前三季业绩增长三成能否撑起 减持股份",
            "features": {
                "keywords": [
                    "贝达药业",
                    "控股股东",
                    "减持",
                    "1673万股",
                    "前三季业绩",
                    "增长三成"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业控股股东减持1673万股前三季业绩增长三成能否撑起 减持股份",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]